Skip to main content
. 2022 Sep 20;12:916988. doi: 10.3389/fonc.2022.916988

Table 3.

MRI features of TNBC-MC and TNBC-NMC in the training and validation set.

Training set (n=88) Validation set (n=29)
NMC (n=68) MC (n=20) P value NMC (n=20) MC (n=9) P value
Size (mm) 0.269 0.143
 ≤20 18 (26.5%) 2 (10.0%) 5 (25.0%) 1(11.2%)
 >20and≤50 36 (52.9%) 14 (70.0%) 13(65.0%) 4 (44.4%)
 >50 14 (20.6%) 4 (20.0%) 2 (10.0%) 4 (44.4%)
T1WI 0.075 0.287
 Hyperintense 4 (5.9%) 4 (20%) 2 (10%) 3 (33.3%)
 Hypo or isointense 64 (94.1%) 16 (80%) 18 (90%) 6 (66.7%)
T2WI 0.318 1.000
 Iso or hyper intense 65 (95.6%) 18 (80.0%) 18 (90.0%) 9(100%)
 Hypointense 3 (4.4%) 2 (20.0%) 2 (10.0%) 0
Lesion type 0.001 0.066
 Mass 36 (52.9%) 19 (95.0%) 13 (65.0%) 9 (100%)
 Nonmass & both 32 (47.1%) 1 (5.0%) 7 (35.0%) 0 (0.0%)
Shape 0.543 1.000
 Round/oval 19 (27.9%) 7 (35.0%) 8 (40.0%) 4 (44.4%)
 Irregular 49 (72.1%) 13 (65.0%) 12 (60.0%) 5 (55.6%)
Margin 0.481 0.287
 Circumscribed 9 (13.2%) 4 (20.0%) 2 (10.0%) 6 (66.7%)
 Not clear 59 (86.8%) 16 (80.0%) 18 (90.0%) 3 (33.3%)
Internal enhancement pattern 0.029 0.209
 Heterogeneous 50 (73.5%) 9 (45.0%) 16 (80.0%) 5 (55.6%)
 Rim enhancement 18 (26.5%) 11 (55.0%) 4 (20.0%) 4 (44.4%)

TNBC,triple-negative breast cancer; MC, metaplastic carcinoma; NMC, non-metaplastic carcinoma.

Bold means P values ≤0.05 were considered statistically significant.